Literature DB >> 21670200

Proteolytically cleaved MLL subunits are susceptible to distinct degradation pathways.

Akihiko Yokoyama1, Francesca Ficara, Mark J Murphy, Christian Meisel, Alpana Naresh, Issay Kitabayashi, Michael L Cleary.   

Abstract

The mixed lineage leukemia (MLL) proto-oncogenic protein is a histone-lysine N-methyltransferase that is produced by proteolytic cleavage and self-association of the respective functionally distinct subunits (MLL(N) and MLL(C)) to form a holocomplex involved in epigenetic transcriptional regulation. On the basis of studies in Drosophila it has been suggested that the separated subunits might also have distinct functions. In this study, we used a genetically engineered mouse line that lacked MLL(C) to show that the MLL(N)-MLL(C) holocomplex is responsible for MLL functions in various developmental processes. The stability of MLL(N) is dependent on its intramolecular interaction with MLL(C), which is mediated through the first and fourth plant homeodomain (PHD) fingers (PHD1 and PHD4) and the phenylalanine/tyrosine-rich (FYRN) domain of MLL(N). Free MLL(N) is destroyed by a mechanism that targets the FYRN domain, whereas free MLL(C) is exported to the cytoplasm and degraded by the proteasome. PHD1 is encoded by an alternatively spliced exon that is occasionally deleted in T-cell leukemia, and its absence produces an MLL mutant protein that is deficient for holocomplex formation. Therefore, this should be a loss-of-function mutant allele, suggesting that the known tumor suppression role of MLL may also apply to the T-cell lineage. Our data demonstrate that the dissociated MLL subunits are subjected to distinct degradation pathways and thus not likely to have separate functions unless the degradation mechanisms are inhibited.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21670200      PMCID: PMC3113671          DOI: 10.1242/jcs.080523

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  73 in total

1.  Clonal expansion of non-leukemic cells expressing two novel MLL-ELL variants differing in transforming activity.

Authors:  M Takeuchi; C Nakaseko; S Miyagi; Y Takeda; S Ozawa; C Ohwada; R Cho; M Nishimura; Y Saito; A Iwama
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

2.  Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia.

Authors:  Tim C P Somervaille; Michael L Cleary
Journal:  Cancer Cell       Date:  2006-10       Impact factor: 31.743

3.  The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML.

Authors:  Yingzi Wang; Andrei V Krivtsov; Amit U Sinha; Trista E North; Wolfram Goessling; Zhaohui Feng; Leonard I Zon; Scott A Armstrong
Journal:  Science       Date:  2010-03-26       Impact factor: 47.728

Review 4.  MLL translocations, histone modifications and leukaemia stem-cell development.

Authors:  Andrei V Krivtsov; Scott A Armstrong
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

5.  Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia.

Authors:  Emilie Le Toriellec; Gilles Despouy; Gaëlle Pierron; Nogaye Gaye; Marjorie Joiner; Dorine Bellanger; Anne Vincent-Salomon; Marc-Henri Stern
Journal:  Blood       Date:  2007-12-11       Impact factor: 22.113

6.  Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines.

Authors:  Takeaki Dohda; Aljona Maljukova; Lining Liu; Mats Heyman; Dan Grandér; David Brodin; Olle Sangfelt; Urban Lendahl
Journal:  Exp Cell Res       Date:  2007-05-05       Impact factor: 3.905

7.  Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal.

Authors:  Kathryn A McMahon; Samantha Y-L Hiew; Suzana Hadjur; Henrique Veiga-Fernandes; Ursula Menzel; Amanda J Price; Dimitris Kioussis; Owen Williams; Hugh J M Brady
Journal:  Cell Stem Cell       Date:  2007-09-13       Impact factor: 24.633

8.  Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors.

Authors:  Craig D Jude; Leslie Climer; Diyong Xu; Erika Artinger; Jill K Fisher; Patricia Ernst
Journal:  Cell Stem Cell       Date:  2007-09-13       Impact factor: 24.633

9.  Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions.

Authors:  Han Liu; Emily H-Y Cheng; James J-D Hsieh
Journal:  Genes Dev       Date:  2007-10-01       Impact factor: 11.361

10.  Molecular evidence for hierarchical transcriptional lineage priming in fetal and adult stem cells and multipotent progenitors.

Authors:  Robert Månsson; Anne Hultquist; Sidinh Luc; Liping Yang; Kristina Anderson; Shabnam Kharazi; Suleiman Al-Hashmi; Karina Liuba; Lina Thorén; Jörgen Adolfsson; Natalija Buza-Vidas; Hong Qian; Shamit Soneji; Tariq Enver; Mikael Sigvardsson; Sten Eirik W Jacobsen
Journal:  Immunity       Date:  2007-04-12       Impact factor: 31.745

View more
  19 in total

1.  ECSASB2 mediates MLL degradation during hematopoietic differentiation.

Authors:  Jingya Wang; Andrew G Muntean; Jay L Hess
Journal:  Blood       Date:  2011-12-15       Impact factor: 22.113

2.  Augmented generation of protein fragments during wakefulness as the molecular cause of sleep: a hypothesis.

Authors:  Alexander Varshavsky
Journal:  Protein Sci       Date:  2012-11       Impact factor: 6.725

3.  Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia.

Authors:  Kaiwei Liang; Andrew G Volk; Jeffrey S Haug; Stacy A Marshall; Ashley R Woodfin; Elizabeth T Bartom; Joshua M Gilmore; Laurence Florens; Michael P Washburn; Kelly D Sullivan; Joaquin M Espinosa; Joseph Cannova; Jiwang Zhang; Edwin R Smith; John D Crispino; Ali Shilatifard
Journal:  Cell       Date:  2017-01-05       Impact factor: 41.582

4.  TBP loading by AF4 through SL1 is the major rate-limiting step in MLL fusion-dependent transcription.

Authors:  Hiroshi Okuda; Satoshi Takahashi; Akifumi Takaori-Kondo; Akihiko Yokoyama
Journal:  Cell Cycle       Date:  2016-08-26       Impact factor: 4.534

5.  An MLL-dependent network sustains hematopoiesis.

Authors:  Erika L Artinger; Bibhu P Mishra; Kristin M Zaffuto; Bin E Li; Elaine K Y Chung; Adrian W Moore; Yufei Chen; Chao Cheng; Patricia Ernst
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-06       Impact factor: 11.205

Review 6.  Molecular mechanisms of MLL-associated leukemia.

Authors:  Akihiko Yokoyama
Journal:  Int J Hematol       Date:  2015-03-17       Impact factor: 2.490

7.  Novel sub-cellular localizations and intra-molecular interactions may define new functions of Mixed Lineage Leukemia protein.

Authors:  Amit Mahendra Karole; Swathi Chodisetty; Aamir Ali; Nidhi Kumari; Shweta Tyagi
Journal:  Cell Cycle       Date:  2018-12-10       Impact factor: 4.534

Review 8.  Diverse functions of PHD fingers of the MLL/KMT2 subfamily.

Authors:  Muzaffar Ali; Robert A Hom; Weston Blakeslee; Larissa Ikenouye; Tatiana G Kutateladze
Journal:  Biochim Biophys Acta       Date:  2013-11-28

9.  A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)-mediated E3 ligase activity.

Authors:  Jingya Wang; Andrew G Muntean; Laura Wu; Jay L Hess
Journal:  J Biol Chem       Date:  2012-11-05       Impact factor: 5.157

10.  HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma.

Authors:  Shugaku Takeda; Han Liu; Satoru Sasagawa; Yiyu Dong; Paul A Trainor; Emily H Cheng; James J Hsieh
Journal:  J Clin Invest       Date:  2013-06-24       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.